CIDP response to Ig: What, When and How? How? Ig‘s Mechanism of action and its relationship with clinical outcomes. Dr. med. Kalliopi Pitarokoili - Bochum, Germany Duration : 18:18 When? Therapeutic Response to Immunoglobulins in CIDP: lessons from the Italian Database. Prof. Eduardo Nobile-Orazio - Milan , Italy Duration - 12:31 What? Best outcomes measure in clinical practice Prof. Yusuf Rajabally - Birmingham, UK Duration - 23:29 HomeAbout EquilYbriumSteering Committee membersImmunodeficienciesPrimary ImmunodeficienciesADVANCED CARE IN PID: From birth to adulthood: LFB Symposium IPIC 2015THE IMMUNOLOGIST CONSULTATION; Recognizing the signs of X-linked agammaglobulinemiaNEW INSIGHTS IN THE USE OF INTRAVENOUS IMMUNOGLOBULINS: How to enhance PID patients clinical outcomes ?Secondary ImmunodeficienciesSID IN A HEART TRANSPLANT PATIENTSID IN CLL PATIENTImmunomodulationGuillain-Barré Syndrome (GBS)Guillain Barré Syndrome : From diagnosis to treatmentChronic Inflammatory Demyelinating Polyneuropathy (CIDP)CIDP Educational Slides DeckNew insights in the use of intravenousimmunoglobulinsSerious game: NeuroSimsCIDP response to Ig: What, When and How?CIDP: Early treatment escalation in non-IVIg responders. A debateMultifocal Motor neuropathy (MMN)Evidence - based medicine and current advances in multifocal motor neuropathyCongresses highlightsPNS 2020 Congress - Selected research presentationPNS - ICNMD 2022 congresses - Selected research presentationsGuidelinesEAN/PNS CIDP Guidelines 2021 - Dr. Luis Querol LectureResearch Grant × You will be redirected to the page : Presentation of the Grant I accept ▸